We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+66.84%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$807M
Cap. Flow
+$35.6M
Cap. Flow %
1.56%
Top 10 Hldgs %
52.32%
Holding
69
New
7
Increased
11
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$37.5M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$36.1M
3
AMRN
Amarin Corp
AMRN
+$32.7M
4
RNAM
Avidity Biosciences
RNAM
+$32.3M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.8M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$65.9M
2
IMMU
Immunomedics Inc
IMMU
+$53.9M
3
RCUS icon
Arcus Biosciences
RCUS
+$27M
4
SAGE
Sage Therapeutics
SAGE
+$15.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$8.82M

Sector Composition

Rank Sector Weight
1 Healthcare 85.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.42B
$31.3M 1.38%
2,202,812
+1,438,560
+188% +$11.3M
DBVT
27
DBV Technologies
DBVT
$799M
$30.9M 1.36%
703,460
– –
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$11.6B
$30.8M 1.36%
250,000
– –
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$340M
$30.7M 1.35%
1,466,051
– –
ANAB icon
30
AnaptysBio
ANAB
$1.58B
$29M 1.28%
1,300,000
– –
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$24.4M 1.07%
2,400,000
+1,200,000
+100% +$11M
LABD icon
32
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$24.3M 1.07%
35,000
+28,750
+460% +$36.1M
BLU
33
DELISTED
BELLUS Health Inc.
BLU
$18.3M 0.8%
1,775,000
– –
ACAD icon
34
Acadia Pharmaceuticals
ACAD
$4.43B
$17.9M 0.79%
370,000
– –
CABA icon
35
Cabaletta Bio
CABA
$437M
$17.4M 0.77%
1,566,361
– –
NGNE icon
36
Neurogene
NGNE
$656M
$16.8M 0.74%
50,463
– –
PRVL
37
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$16.7M 0.74%
1,123,105
– –
GBT
38
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.8M 0.69%
250,000
– –
AGEN
39
Agenus
AGEN
$312M
$15.7M 0.69%
203,800
– –
KURA icon
40
Kura Oncology
KURA
$800M
$13.8M 0.61%
844,789
– –
RLMD icon
41
Relmada Therapeutics
RLMD
$557M
$13.4M 0.59%
300,000
– –
CLDX icon
42
Celldex Therapeutics
CLDX
$2.99B
$13M 0.57%
+1,000,000
New +$4.43M
FULC icon
43
Fulcrum Therapeutics
FULC
$239M
$12.9M 0.57%
+705,882
New +$11.1M
MREO
44
Mereo BioPharma
MREO
$54.7M
$12.3M 0.54%
4,029,649
+1,579,106
+64% +$2.79M
LITS
45
Lite Strategy Inc
LITS
$32.8M
$12M 0.53%
145,655
– –
AKRO
46
DELISTED
Akero Therapeutics
AKRO
$10.4M 0.46%
416,495
– –
KOD icon
47
Kodiak Sciences
KOD
$2.6B
$9.8M 0.43%
181,138
+31,138
+21% +$1.76M
RNAC icon
48
Cartesian Therapeutics
RNAC
$229M
$9.33M 0.41%
109,469
– –
MTNB icon
49
Matinas BioPharma
MTNB
$1.88M
$8.87M 0.39%
229,573
– –
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.06B
$7.52M 0.33%
600,000
– –
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Boxer Capital held 69 positions worth $2.27B, up 55% from $1.47B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital's Q2 2020 filing shows 7 new, 11 increased, 6 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M. The largest sale was Regeneron Pharmaceuticals, an estimated $65.9M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

  • Boxer Capital's largest Q2 2020 buy was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q2 2020, an estimated $36.1M increase.
  • Boxer Capital's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $53.9M.
  • Boxer Capital fully exited Regeneron Pharmaceuticals in Q2 2020, selling an estimated $65.9M.
  • Boxer Capital's ten largest holdings make up 52% of its $2.27B portfolio in Q2 2020.
  • Boxer Capital opened 7 new positions and closed 4 in Q2 2020.
  • Boxer Capital's portfolio value rose 55% quarter-over-quarter to $2.27B.

Based on Boxer Capital's 13F filing for Q2 2020, filed 14 Aug 2020.